(Boursier.com) — IntegraGen reveals a turnover of 5.6 MEUR in the first half of 2023, down 13% compared to H1 2022 and a cash position of 4.3 MEUR.
The company mentions a drop in the activity of the microbiology sequencing platform after a strong contribution recorded in the 1st half of 2022 in the context of the Covid-19 pandemic. Restated for this base effect, growth was 6% over the period.
Inégragen also reports a slight decrease in revenue recognized by the sequencing platform for R&D in Evry.
©2023 Boursier.com